ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 9, 2024
KEY HIGHLIGHTS
WESTON, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended June 30, 2024, and provides business update.
Read more at globenewswire.com
